Interventions to reduce tuberculosis mortality: a systematic review and metaanalysis of trial evidence

L. Quevedo,^{1,2,3} R. Montoya,^{2,3} P. Tapia,^{2,3} R. Sosa,^{2,3} M. Rivero,^{2,3} J. Gómez,^{2,3} S. Datta,^{2,3,4} M. Saunders,¹ P.P. Carballo-Jimenez,^{1,2,3} C.A. Evans,^{1,2,3} ¹IFHAD: Innovation For Health And Development, Imperial College London, Dept of Infectious Disease, London, Peru, ²IFHAD: Innovation For Health And Development, Universidad Peruana Cayetano Heredia, Laboratory of Research and Development, Lima, Peru, ³Innovación Por la Salud Y el Desarrollo (IPSYD), Asociación Benéfica PRISMA, Lima, Peru, ⁴Liverpool School of Tropical Medicine, Clinical Sciences, Liverpool, United Kingdom of Great Britain and Northern Ireland

Type selection

Category: Scientific research

Prefered presentation type: Oral abstract presentation

Track selection

Track: B7: TB and comorbidities (HIV, diabetes, malnutrition, mental health, etc.) 2nd Track: D5: Infection prevention and control of TB (and other airborne diseases affecting lung health e.g. SARS CoV-2)

<u>Title</u>

Scientific Research Abstract Text

Background:

Tuberculosis is believed to have killed more people than any other infection. We aimed to synthesize the trial evidence assessing interventions aiming to reduce tuberculosis mortality.

Design/Methods:

Our systematic review of the PUBMED database followed the Prisma 2020 checklist and used search terms "(tuberculosis OR TB) AND (death OR mortality OR fatality OR survival)". We selected and characterized the eligible randomized controlled trials that included death as a primary or secondary outcome (including populations with comorbidities such as HIV). We did a meta-analysis of time-to-event data using the software RevMa 5.4 (Review Manager). A fixed-effects model was applied to estimate the pooled relative risks (RR) and hazard ratios (HR), and 95% confidence intervals (CI).

Results:

Disado, es	Talk antist		HARACE Code	
Witcor, 1988	160 ng sufamethosanik and 80 ng tronethogram sa Pacebo	0	114 (14-1.0)	
Bare, 2008	400 ng sufanahosasis ani 80 ng sinahapin si Rasia	0	1.79 (0.4-1)	
(a trimosocile as placeter		•	871 (84.470 p-8.00)	
Range, (1906	WWW-day in Pacific Pacific		85282-128	Of the 2268 identified articles, there were 29 trials, only 7 of which were eligible (Figure). Two studies
Range, 2008	WW Roden Role Role		047(0.4-1.7)	
Aurga, 2006	Die Pasite is Pasite Pasite		0905-17	
levela, 2007	Monautant e. Pacele	4	0.00(0.8-12)	
Vilano; 200	Moundait e. Paste	-	53408-540	
Wique, 2009	Onlecal/Arrol vi, Raceles	· • • • • • • • • • • • • • • • • • • •	13808-411	
All matrillan on placebo		+		
Mercentrient without disc or p	fanthe	+		
Randon, 2022	Gasity improvement is, Standard of Law	+	1.07.06-1.0	
		111111		

included HIV-positive populations with TB and evaluated the effects of co-trimoxazole that caused a 29% decrease in the hazard of death (HR=0.71, 95%CI=0.58-0.86, p<0.001). Four studies all reported no significant effect of micronutrient supplementation on mortality (HR=0.95, 95%CI=0.81-1.1, p=0.5). Subgroup analysis of micronutrient supplementation without zinc also revealed no effect on mortality (HR:1.0, 95%CI=0.78-1.3, p=0.8). A quality improvement study also found no significant effect on mortality (HR=0.92 95%CI=0.63-1.3).

Conclusions: Micronutrient supplementation and a quality improvement intervention had no significant effect whereas in two studies of people with TB-HIV co-infection, co-trimoxazole significantly reduced mortality. Remarkably few trials have focused on reducing tuberculosis mortality.

<u>Summary</u>

Summary:

No aspect of TB is more important than preventing mortality, one of the WHO End TB priorities. We therefore assessed trial evidence assessing interventions to reduce TB mortality. We found remarkably few trials, and meta-analysis revealed evidence that co-trimoxazole reduced TB mortality, not micronutrient supplements nor quality improvement did not.

Other Fields

Country of research: Peru Did you benefit from the <u>Abstract Mentor Programme (AMP)?</u>: No Do you have ethical clearance for this abstract?: No If not, please specify why: Not needed because all publicly available data.

Confirm submission

1. I confirm that I have previewed this abstract and that all information is correct.: Yes

2. I agree to the resubmission policy.: Yes

- 3. I have read the Stigmatising Language Policy, and confirm I have not used stigmatising language in the abstract.: Yes
- 4. The corresponding author is responsible for informing the other authors.: $\ensuremath{\mathsf{Yes}}$

5. If accepted, I hereby agree to the attached information relating to the release, recording and publication of the presentations and

session.: Yes

6. I understand that my abstract if accepted may be used by the Scientific Committee of The Union for the rapporteur session or shared with the media team. The media and communication teams may use the summary of the abstract for advertisement of the conference content.: Yes

Do you intend to apply for a scholarship? (After notifications are sent).: Yes